Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

NCT06914141 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of two medications, tirzepatide and semaglutide, in adults with type 2 diabetes who also have heart failure with preserved ejection fraction.

Status Completed The study has finished.

Type Observational

Participants 28,118 people

Who can join Ages 18+ · all sexes

Timeline Started 2025-01 · est. completion 2025-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06914141 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Tirzepatide Drug

New use of tirzepatide dispensing claim is used as the exposure.
Semaglutide Drug

New use of semaglutide dispensing claim is used as the reference.

Main thing measured	Composite of all-cause mortality or heart failure hospitalization
Sponsor	Brigham and Women's Hospital
Conditions studied	Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06914141 ↗